X
[{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"$2,300.0 million","upfrontCash":"Undisclosed","newsHeadline":"UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by Ra Pharmaceuticals
Filters
Companies By Therapeutic Area
Details:
The transaction will enhance UCB’s potential to be a leader in myasthenia gravis by adding zilucoplan, currently in phase 3, to the UCB pipeline alongside rozanolixizumab.
Lead Product(s):
Zilucoplan Sodium
Therapeutic Area: Musculoskeletal
Product Name: Undisclosed
Highest Development Status: Phase III
Product Type: Peptide
Partner/Sponsor/Collaborator:
UCB Pharma S.A
Deal Size: $2,300.0 million
Upfront Cash: Undisclosed
Deal Type: Acquisition
April 02, 2020
Details:
the study demonstrated that zilucoplan resulted in rapid, clinically meaningful, statistically significant, and sustained improvements in the primary and key secondary endpoints.
Lead Product(s):
Zilucoplan Sodium
Therapeutic Area: Musculoskeletal
Product Name: Undisclosed
Highest Development Status: Phase III
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 18, 2020
Details:
Zilucoplan was selected as one of the first clinical candidates to be evaluated in this platform trial for ALS led by the Sean M. Healey & AMG Center for ALS at Mass General.
Lead Product(s):
Zilucoplan Sodium
Therapeutic Area: Neurology
Product Name: Undisclosed
Highest Development Status: IND Enabling
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 22, 2020